Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation

CompletedOBSERVATIONAL
Enrollment

514

Participants

Timeline

Start Date

May 4, 2022

Primary Completion Date

June 1, 2022

Study Completion Date

June 1, 2022

Conditions
2019 Novel Coronavirus Disease2019 Novel Coronavirus Infection2019-nCoV DiseaseCOVID-19 PandemicCOVID-19 Virus DiseaseCOVID-19 Virus InfectionCoronavirus Disease 2019Coronavirus Disease-19SARS-CoV-2 Infection
Interventions
DEVICE

Diagnostic Test: Diagnostic Software as Medical Device

AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses, specifically COVID-19 illness for this study.

Trial Locations (1)

33325

Sunrise Research Institute, Sunrise

Sponsors
All Listed Sponsors
collaborator

Sunrise Research Institute

UNKNOWN

collaborator

Analytical Solutions Group, Inc.

UNKNOWN

collaborator

Kelley Medical Consultants LLC

UNKNOWN

collaborator

R. P. Chiacchierini Consulting, LLC

INDUSTRY

lead

AudibleHealth AI, Inc.

INDUSTRY

NCT05364268 - Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation | Biotech Hunter | Biotech Hunter